Incyte
| Company type | Public |
|---|---|
| Industry | Pharmaceutical |
| Headquarters | Wilmington, Delaware , United States |
Area served | Worldwide |
Key people | Hervé Hoppenot (President, CEO, and Chairman) |
| Products | Jakafi, Pemazyre, Monjuvi, Opzelura, Tabrecta, Olumiant, Iclusig |
Incyte Corporation is a global American pharmaceutical enterprise with its main office located in Wilmington, Delaware. The company maintains production and research facilities throughout North America, Europe, and Asia, concentrating on biopharmaceutical innovations targeting oncology, autoimmune disorders, and inflammatory diseases.
History
Hervé Hoppenot assumed the roles of president and CEO in 2014 and was named chairman of the Board in 2015. Prior to joining Incyte, Hoppenot gained significant expertise as the president of Novartis Oncology.
In September 2015, Incyte obtained exclusive rights for development and commercialization of the anti-PD-1 monoclonal antibody SHR-1210 from Jiangsu Hengrui Medicine, in a transaction valued at over $795 million.
A global collaboration and licensing deal with MorphoSys was established in January 2020 for tafasitamab. This agreement granted Incyte co-commercialization rights within the United States and exclusive commercialization rights internationally. The partnership was completed after receiving antitrust approval in March 2020.
To bolster its worldwide presence, Incyte inaugurated a European headquarters in Morges, Switzerland in 2021, facilitating enhanced engagement with clinical trial specialists and expediting drug development processes.
Pharmaceuticals
The company offers seven pharmaceutical products: Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (ruxolitinib), Tabrecta (capmatinib), Olumiant (baricitinib), and Iclusig (ponatinib).
In 2013, Novartis acquired capmatinib, a c-Met inhibitor originally developed by Incyte and marketed as Tabrecta. By 2014, Incyte was advancing baricitinib—an oral inhibitor targeting JAK1 and JAK2 for rheumatoid arthritis—in collaboration with Eli Lilly. The European Union granted approval for the medication in February 2017. Although the U.S. FDA initially declined approval in April 2017 due to concerns regarding dosage and safety, baricitinib received FDA approval in May 2018 under the brand name Olumiant.
As of 2016, Incyte was progressing with epacadostat development, an IDO1 inhibitor aimed at multiple cancer types. Clinical trials included combination therapies with pembrolizumab (Keytruda) from Merck and nivolumab (Opdivo) from Bristol Myers Squibb.
In May 2024, Incyte expanded its global footprint and product lineup by completing a $750 million acquisition of Escient Pharmaceuticals.